Pembrolizumab-CRT: The New Standard of Care in Locally Advanced Cervical Cancer?

MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...

info product website showcasing more than 7000ebooks

+